Close X

CEDA 2024: Hype or hope? Diabetes technology in practice

04th July 2024

People living with diabetes have to make hundreds of decisions each day to manage their disease. Diabetes technology promises to ease this burden, but how effective is it in practice? This was one of the questions discussed at a joint session of the Central European Diabetes Association (CEDA) and the European Association for the Study of Diabetes (EASD) at the CEDA Congress, which touched on some of the most widely debated issues in diabetes care. In the following video, Julia Mader shares insights from the joint session and her presentation.

Since the world’s first insulin was injected into a human a century ago, efforts focused mainly on improving insulin treatment for diagnosed patients. Today, preventive therapy is being researched as the next milestone, and an increasing number of countries are discussing strategies to identify the target population for such treatments. To this end, existing data sets from observational cohort studies can be used together with known risk predictors such as islet autoantibodies, human leukocyte antigen (HLA) haplotypes and genetic risk scores. The challenge now is to translate this knowledge into effective screening strategies.

Lessons from the “real world”

An observational study published in Diabetes Care found that people with type 1 diabetes were more likely to achieve recommended glycaemic targets when using diabetes technologies, particularly sensor-augmented pumps with low glucose management and automated insulin delivery. However, “all that glitters is not gold,” Mader cautions. While diabetes technologies hold great promise, there are also downsides, such as alarm fatigue and stigma due to the visibility of the devices. Another major challenge is the lack of interoperability between technologies, as recently highlighted in Diabetologia; the paper in question discusses both the practical difficulties of connecting devices from different manufacturers as well as regulatory issues. “We hope that in the future, more interoperability will improve diabetes management,” says co-author Mader.

Putting new technologies into practice

For diabetologists interested in diabetes technology, Mader’s advice is simple: “Don’t be shy to try out new technologies!” She emphasises the importance of gaining expertise in different systems and of collaborating with industry, especially when it comes to educating people with diabetes. Finally, Mader encourages diabetologists to try the systems themselves and “walk some miles in your patients’ shoes”.

EASD/CEDA Joint Symposium
Chairs: Francesco Giorgino (Italy), Peter Kempler (Hungary), Anca Pantea Stoian (Romania)
  • Julia Mader (Austria): Beyond the hype: navigating the promise and reality of novel technologies in type 1 diabetes management
  • Christian Herder (Germany): Precision Diabetology – where do we stand now?
  • Manfredi Rizzo (Italy): The cardiometabolic continuum from overweight/obesity to prediabetes/type 2 diabetes: a modern approach
  • Francesco Giorgino (Italy): Building on GLP-1 pleiotropic effects: new players and new indications at the horizon

To learn more about the CEDA, go to:

Author: Hanna Gabriel, BA MSc. Any opinions expressed in this article are the responsibility of EASD e-Learning.